These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28414206)

  • 1. Wenshen Zhuanggu formula effectively suppresses breast cancer bone metastases in a mouse Xenograft model.
    Li JJ; Chen WL; Wang JY; Hu QW; Sun ZP; Zhang S; Liu S; Han XH
    Acta Pharmacol Sin; 2017 Oct; 38(10):1369-1380. PubMed ID: 28414206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-metastatic effect and mechanisms of Wenshen Zhuanggu Formula in human breast cancer cells.
    Han XH; Wang CL; Xie Y; Ma J; Zhang XH; Hu QW; Lin G; Liu S; Lu JG
    J Ethnopharmacol; 2015 Mar; 162():39-46. PubMed ID: 25554638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wenshen Zhuanggu formula mitigates breast cancer bone metastasis through the signaling crosstalk among the Jagged1/Notch, TGF-β and IL-6 signaling pathways.
    Wu C; Chen M; Sun Z; Ye Y; Han X; Qin Y; Liu S
    J Ethnopharmacol; 2019 Mar; 232():145-154. PubMed ID: 30576770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics of six coumarins in normal and breast cancer bone-metastatic mice after oral administration of Wenshen Zhuanggu Formula.
    Chen W; Li J; Sun Z; Wu C; Ma J; Wang J; Liu S; Han X
    J Ethnopharmacol; 2018 Oct; 224():36-44. PubMed ID: 29803570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WSZG inhibits BMSC-induced EMT and bone metastasis in breast cancer by regulating TGF-β1/Smads signaling.
    Ma J; Li J; Wang Y; Chen W; Zheng P; Chen Y; Sun Z; Liu J; Zhou Y; Wang J; Liu S; Han X
    Biomed Pharmacother; 2020 Jan; 121():109617. PubMed ID: 31810139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
    Hiraga T; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
    Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
    Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
    Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive effects of zoledronic acid on bone metastasis in mice injected with human breast cancer cells.
    Jeong J; Lee KS; Choi YK; Oh YJ; Lee HD
    J Korean Med Sci; 2011 Dec; 26(12):1569-75. PubMed ID: 22147993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
    Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR
    Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
    Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
    Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
    Wright LE; Harhash AA; Kozlow WM; Waning DL; Regan JN; She Y; John SK; Murthy S; Niewolna M; Marks AR; Mohammad KS; Guise TA
    Oncotarget; 2017 Jan; 8(5):8406-8419. PubMed ID: 28039445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
    Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
    Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
    Peyruchaud O; Winding B; Pécheur I; Serre CM; Delmas P; Clézardin P
    J Bone Miner Res; 2001 Nov; 16(11):2027-34. PubMed ID: 11697798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells.
    Nakata A; Tsujimura T; Sugihara A; Okamura H; Iwasaki T; Shinkai K; Iwata N; Kakishita E; Akedo H; Terada N
    Anticancer Res; 1999; 19(5B):4131-8. PubMed ID: 10628364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis.
    Harms JF; Welch DR; Samant RS; Shevde LA; Miele ME; Babu GR; Goldberg SF; Gilman VR; Sosnowski DM; Campo DA; Gay CV; Budgeon LR; Mercer R; Jewell J; Mastro AM; Donahue HJ; Erin N; Debies MT; Meehan WJ; Jones AL; Mbalaviele G; Nickols A; Christensen ND; Melly R; Beck LN; Kent J; Rader RK; Kotyk JJ; Pagel MD; Westlin WF; Griggs DW
    Clin Exp Metastasis; 2004; 21(2):119-28. PubMed ID: 15168729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.
    Ottewell PD; Wang N; Brown HK; Reeves KJ; Fowles CA; Croucher PI; Eaton CL; Holen I
    Clin Cancer Res; 2014 Jun; 20(11):2922-32. PubMed ID: 24687923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
    Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
    Hiraga T; Ueda A; Tamura D; Hata K; Ikeda F; Williams PJ; Yoneda T
    Int J Cancer; 2003 Oct; 106(6):973-9. PubMed ID: 12918079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plumbagin attenuates cancer cell growth and osteoclast formation in the bone microenvironment of mice.
    Yan W; Wang TY; Fan QM; Du L; Xu JK; Zhai ZJ; Li HW; Tang TT
    Acta Pharmacol Sin; 2014 Jan; 35(1):124-34. PubMed ID: 24384612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.